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Extraskeletal Osteosarcoma
Background
. About 1% of all soft tissue sarcomas
. First described by Wilson in 1941
. Few large series then reported
. Older individuals & usually worse survival
than skeletal osteosarcoma
Extraskeletal Osteosarcoma
Diagnostic Criteria
. Arise in the soft tissue and not
be attached to bone/periosteum
Extraskeletal Osteosarcoma
Diagnostic Criteria
. Uniform sarcomatous pattern, high-grade
. Produce osteoid-bone/cartilage matrix
Extraskeletal Osteosarcoma
Classic Literature: 80’s-90’s
- 26-88 pts, 1915-1988, all high-grade lesions
- Mean age 51-55 yrs, M:F=1-1.9, 47-68% lower limb
- Mgmt: mostly surgical unimodal, little role for Rxt/Cht
- LR 43-69%, mets 61-80%, 5yr OS rate 24-37%
- Suggested role for tumor size, surgical margin and    
possibly aggressive multimodal management
MSKCC - Sordillo PP et al, Cancer, 1983
AFIP  - Chung EB & Enzinger FM, Cancer, 1987
MDACC  - Bane BL et al, Cancer, 1990
Mayo Clinic - Lee JS et al, Cancer, 1995
Extraskeletal Osteosarcoma
Recent Literature
- 17-38 pts, 12-20 yrs experience, all high-grade lesions
- Mean age 44-55 yrs, M:F=1-2, 47-52% lower limb
- Mgmt: mostly multimodal - Surgery & Cht, less Rxt 
- LR 16-29%, mets 7-39%, 3yr EFS 56%, 5yr EFS 47%
5ys OS rate 46-66%                            
- Improved outcome, better surgical margin, Cht likely
beneficial even if questionable clin/path response
MDACC - Ahmad SA et al, J Clin Oncol, 2002
Munster - Goldstein-Jackson SY et al, J Cancer Res Clin Oncol, 2005
Japan, multicentric - Torigoe T et al, J Orthop Sci, 2007
Extraskeletal Osteosarcoma
Rizzoli Experience
. 48 pts, 1966-2007, 36 admitted, 12 consults
. Clinico-path & radiologic features reviewed
. Management correlated with outcome
. Updated FU obtained in all patients
. Kaplan Meier & log rank survival analysis
Extraskeletal Osteosarcoma
Rizzoli Experience
. Median age 53.6 yrs, M 21/F15, LL 69% 
. Prox 52.8%, Distal 16.7%, Girdles 30.6%
. All high-grade lesions; def Dx on specimen 16 (44%)
. 23 pts localised (64%), 13 metastatic (36%)
. 16 prev. excision admitted for further surgery 
Extraskeletal Osteosarcoma
. Surgery: 34 (LS 69.5%, amp 25%), 2 inop.
. Margins: adequate 76.5%, inadequate 23.5%
. Cht 19 (52.8%): 17 adjuv postop, 2 neoadjuv
- 2 to 4 drugs regimen based on pt age
. Postoperative Rxt: 6 patients (16.7%)
Rizzoli Experience: Management
Extraskeletal Osteosarcoma
Expected Overall Survival
Median FU: 58 months
41%
31%
Extraskeletal Osteosarcoma
Expected Event-Free Survival
Median FU: 5.8 yrs
24% 24%
Extraskeletal Osteosarcoma
Overall Survival: Age
p=0.066
Extraskeletal Osteosarcoma
Event-Free Survival: Age
p=0.007
Extraskeletal Osteosarcoma
Overall Survival: Tumor Volume
p=0.01
Extraskeletal Osteosarcoma
Overall Survival: Stage
. 23 pts localised, 9 survivors (1DOC when DF)
- DS survival 43.5% (DFS 39%)
NS
. 13 pts metastatic, 3 survivors (2 AWD, 1 DF)
- DS survival 23% (DFS 7.7%)
Extraskeletal Osteosarcoma
Overall Survival: Margin and LR
. Localised 23, operated 22
- Adequate 18, survivors 8, DFS 44.4%
- Inadequate 4, survivors 2, DFS 50%
- Amputation vs LS: no difference
. 8 pts developed 12 LR’s       further surgery
- 2 pts DF at final FU: 25%
NS
Extraskeletal Osteosarcoma
Overall Survival: Chemotherapy
. Cht: 19 pts, 8 survivors (42.1%)
. No Cht: 17 pts, 5 survivors (29.4%)
NS
Extraskeletal Osteosarcoma
Overall Survival: Chemotherapy
. Localised (23 pts)     improved DFS
- Cht 10 pts: DFS 60%
- No Cht 13 pts: DFS 31% (23%)
. Metastatic (13 pts)
- Cht 9 pts: 1DF, 1 AWD   DFS 11%
- No Cht 4 pts: 1 AWD      DFS   0% 
p=0.09
NS
Extraskeletal Osteosarcoma
Conclusions
. Results comparable with recent literature
. Age and volume important factors
. Worse prognosis than bone OGS ?
. Biologic behavior of aggressive STS
. Cht seems valuable in pts with loc. disease
N. Fabbri
23rd EMSOS Meeting
Birmingham, UK
5th-7th May 2010
Extraskeletal Osteosarcoma
Literature
. Sordillo PP et al, Cancer, 1983 - MSKCC
- 48 pts, 1950-1982, all high-grade lesions
- Mean age 51 yrs, M=F, 54% lower limb, 5 prev Rxt
- Mgmt (45 pts): Surgery 43, Cht in 5 relapses
- LR 69%, mets 80%, LR &/or mets 91%, OS 24%   
- Survivors: amput/resection & Rxt, 4/5 Cht at relapse
Extraskeletal Osteosarcoma
Literature
. Chung EB & Enzinger FM, Cancer, 1987 - AFIP
- 88 pts, 1946-1982, all high-grade lesions
- Mean age 54.6 yrs, M 58%, 46.6% lower limb
- Management: unimodal (surgery), no details
- 2.7 yrs mean FU on 65 pts: LR 43%, mets 63%,   
OS 38.4%, CDFS 12.3%
- Better prognosis of prominent fibroblastic or
MFH-like histologic component
Extraskeletal Osteosarcoma
Literature
. Bane BL et al, Cancer, 1990 - MD Anderson CC
- 26 pts, 1950-1987, all high-grade lesions
- Mean age 53.5 yrs, M:F=1.9, 61.5% lower limb
- Dx: initial biopsy/excision not showing osteoid 
- Mgmt: Surg 9, Surg & Cht 9, Surg & Rxt 3
- 4.6 yrs FU: LR 50%, mets 61%, NED 27%
- Size (< 5 cm vs > 5 cm) main prognostic factor
p < 0.001
- Behaviour more like ST MFH than bone OGS
Extraskeletal Osteosarcoma
Literature
. Lee JS et al, Cancer, 1995 - Mayo Clinic
- 40 pts, 1915-1988, all high-grade lesions
- Mean age 50.7 yrs, M:F=1.9, 68% lower limb
- Management: Surgery 39, Rxt 12, Cht 2
- LR 45%, mets 65%, 5-yr survival 37%, OS 27%
- Positive impact of radical/wide margin and
chondroblastic subtype
Extraskeletal Osteosarcoma
Literature
. Ahmad SY et al, J Clin Oncol, 2002 - MD Anderson CC
- 60 pts, 1960-99, AJCC I=3 ,II=25%, III=43%, IV=28%
- Mean age 55 yrs, M:F=1.6, 52% lower limb
- Management AJCC<IV: Surgery 35, Rxt 6, Cht 24
- LR 20%, mets 40%, 5-yr survival 46% 
- 8 month survival if present with mets
- relatively doxorubicin-resistant, poor-prognosis
ST sarcoma that is distinct from OS
Extraskeletal Osteosarcoma
Literature
. Goldstein-Jackson SY et al, J Cancer Res Clin Oncol, 2005
- 17 pts, 17 insts 1986-2002, all high-grade lesions
- Mean age 44 yrs, M:F=1.7, 47% lower limb
- Management: Surgery 16, Rxt 1, Cht 16
- LR 32%, mets 18%, 5-yr survival 77%
- Positive impact of multi-agent chemotherapy
Extraskeletal Osteosarcoma
Literature
. Torigoe T et al, J Orthop Science, 2007
- 20 pts, 1991-2003, UICC Stage: II=5, III=13, IV=2
- Mean age 50 yrs, M:F=2.3, 60% lower limb
- Management: Surgery 19, Rxt 5, Cht 15
- LR 15%, mets 45%, 5-yr survival 66%
- Positive impact of chemotherapy – similar findings
Extraskeletal Osteosarcoma
Rizzoli Experience
. 48 pts, 1966-2007, 36 admitted, 12 consults
. Clinico-path & radiologic features reviewed
. Management correlated with outcome
. Updated FU obtained in all patients
. Kaplan Meier & log rank survival analysis
Extraskeletal Osteosarcoma
Diagnostic Criteria
. Arise in the soft tissue and not be 
attached to bone/periosteum
. Polyethylene Wear & Hinge Design
. Cemented vs Uncemented Fixation
. Tendon Attachment & Soft Tissue
Sealing
Extraskeletal Osteosarcoma
Unsolved & Controversial Issues
. About 1% of all ST sarcomas
. Wilson H, Ann Surg, 1941
Extraskeletal Osteosarcoma
Unsolved & Controversial Issues
. Deep Infection and Septic Failure
. Polyethylene Wear & Hinge Design
. Cemented vs Uncemented Fixation
. Tendon Attachment & Soft Tissue Sealing
N. Fabbri, MD
Musculoskeletal Tumor Advisory Forum
Rizzoli Orthopaedic Institute
Bologna, Italy
August 26, 2009
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